Risk of joint replacement surgery in Taiwanese female adults with systemic lupus erythematosus: a population-based cohort study

Chien-Han Chen¹, Chia-Wen Hsu² and Ming-Chi Lu³⁴*

Abstract
Background: Female patients with systemic lupus erythematosus (SLE) are prone to have musculoskeletal system involvement, which could lead to joint damage. However, few studies have assessed the incidence of arthroplasty in female patients with SLE. The aim of this study was to investigate the risk of total hip replacement surgery and total knee replacement surgery in patients with SLE.

Methods: We identified 577 female patients with newly diagnosed SLE between 2000 and 2012 using the Taiwan’s National Health Insurance Research Database. A comparison cohort was constructed with female patients without SLE in a ratio of 5:1, based on frequency matching for 10-year age interval, and index year, for each patient with SLE. Both cohorts were followed until a diagnosis of the study outcomes or the end of the follow-up period.

Results: Female patients with SLE showed a significantly higher incidence of receiving total hip replacement surgery (adjusted incidence rate ratio [aIRR] 6.47; \( P < 0.001 \)), but not total knee replacement surgery (aIRR 1.81; \( P = 0.227 \)). Moreover, age-group stratified analyses indicated a high incidence for receiving total hip replacement surgery among young female patients with SLE (aIRR 7.70; \( P = 0.001 \)).

Conclusion: Young female patients with SLE had a high risk of receiving total hip replacement surgery, but not total knee replacement surgery.

Keywords: Systemic lupus erythematosus, Skin and connective tissue diseases, Joint replacement, Replacement arthroplasty

Background
Systemic lupus erythematosus (SLE) is a prototype of systemic autoimmune disease predominately affected women during their childbearing age with an age of onset in late teens and early 40s [1]. Asian countries including Taiwan are at a high risk for developing SLE [2], and the incidence rate was 4.87 per 100,000 population in Taiwan during 2003–2008 [3]. SLE frequently attacks skin, kidney, and nerve, musculoskeletal, and hematological systems, which can lead to increased morbidity and mortality in patients with SLE. The prevalence, clinical manifestations, and severity of SLE vary between different ethnic groups and countries, suggesting different genetic and environmental factors could contribute to the pathogenesis of SLE [4].

Although joint involvement is usually mild and only causing pain over peripheral joints in patients with SLE, current evidence suggests that patients with SLE could have active arthritis, which might lead to joint deformities [5, 6]. In addition, Mertelsmann-Voss et al. reported an increasing risk of receiving arthroplasty over the hip and knee joints in patients with SLE during late 20th to early twenty-first century in the United States [7]. In addition, female patients with SLE are prone to have musculoskeletal involvement compared with male patients [8]. We hypothesized that female patients with

* Correspondence: e360187@yahoo.com.tw

¹Division of Allergy, Immunology and Rheumatology, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, No. 2, Minsheng Road, Dalin, Chiayi 62247, Taiwan
²School of Medicine, Tzu Chi University, Hualien, Taiwan

Full list of author information is available at the end of the article

© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
SLE may have an increased risk of joint damage, leading to an increased need of arthroplasty. Therefore, the purpose of this study was to investigate the risk of total hip replacement surgery (THR) and total knee replacement surgery (TKR) in female patients with SLE using a nationwide, population-based health claims database in Taiwan.

**Methods**

**Study design and data sources**

This study used a nationwide, population-based, retrospective cohort design to analyze the data available from the National Health Insurance Research Database (NHIRD). The study protocol was reviewed and approved by the institutional review board of the Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Taiwan (No. B10104020).

**Identification of the SLE cohort and a comparison cohort**

The methodology in assembling the SLE and comparison cohorts and the identification of outcome variables has been previously described [9]. Using the 2000–2012 catastrophic illness database, female patients with newly diagnosed SLE were defined as new and successful female applicants for the certificate of catastrophic illness with SLE (International Classification of Diseases, Ninth revision, clinical modification, ICD-9-CM code 710.0). In Taiwan, patients who suffer from a list of more than 30 categories of serious diseases, including SLE, is eligible to apply for a catastrophic illness certificates from the National Health Insurance Administration (NHIA) to receive exemption from copayments for healthcare expenses related to their diseases. The certificate is issued to patients only after their medical records and serological reports have been evaluated by the NHIA based on the 1997 American College of Rheumatology (ACR) revised criteria for the classification of SLE [10]. The index date for the SLE patients was defined as the date of the application of catastrophic illness certificate. Women who were age 20.0 to 80.0 years of age on the index date were included in the study.

The comparison cohort was constructed from the 2000 Longitudinal Health Insurance Database (LHID 2000), which contained claims records available from January 1, 2000 to December 31, 2012. The LHID 2000 is a subset of the NHIRD containing health claim data for one million beneficiaries sampled randomly, based on sex and age-group stratification from all health insurance enrollees in the Registry of Beneficiaries of the NHIRD in 2000. It represents approximately 5% of the 23.75 million Taiwanese population enrolled in 2000. To assemble the comparison cohort, five patients were selected, based on frequency matching for 10-year age interval and index year, for each patient with SLE. Patients with SLE were excluded during the selection of the comparison cohort.

**Identification of total hip replacement surgery and total knee replacement surgery**

We followed both the SLE cohort and the comparison cohort to the occurrence of our study events or the end of the follow-up period. The two study events were THR and TKR. A diagnosis of THR and TKR was defined in this study as a principal inpatient ICD-9-CM code 81.51 and 81.54, respectively. Patients in the SLE and comparison cohorts receiving THR and TKR before the index date were excluded. Potential confounders, including fracture of the lower limb (ICD-9-CM codes 820–829) and obesity (ICD-9-CM code 278.0x), were also identified from the LHID 2000.

**Statistical analysis**

We compared the basic characteristics between the SLE cohort and the comparison cohort using t-test or Chi-square test, as appropriate. For the SLE cohort and the comparison cohort, incidence rate per 100,000 person-years was separately calculated for THR and TKR. Incidence rate ratios (IRRs) for the outcome variables were calculated via Poisson regression models (generalized linear models with a Poisson log-linear link function and person-years as the offset variable), with and without adjusting for the potential confounding factors, including fracture of the lower limb and obesity. In addition, subgroup analyses were conducted with stratification by age groups (20–44, 45–64, and 65–80 years). All statistical tests were conducted as two-sided and a P value of < 0.05 was considered significant. All statistical analyses were performed using IBM SPSS Statistics for Windows, Version 24.0 (IBM Corp, Armonk, NY, USA).

**Results**

There are no significant differences between female patients with SLE and comparison cohort in age, socioeconomic status, and geographic region. Patients with SLE have higher proportions of obesity (2.6% vs. 1.4%; P = 0.033) and fracture of the lower limb (8.1% vs. 4.4%; P < 0.001) compared to those in the comparison cohort (Table 1).

The incidence rates and IRRs of THR and TKR for the SLE cohort and the comparison cohort were shown in Table 2. Patients with SLE exhibited a significantly higher incidence of receiving THR compared with the comparison cohort (IRR 8.98; 95% CI: 3.53–22.80, P < 0.001) and adjusted IRR 6.47; 95% CI: 2.43–17.22, P < 0.001, respectively). No significant differences were noted between the IRRs of receiving TKR between the patients with SLE and those of the comparison cohort. Table 3 showed the incidence rates and IRRs of THR and TKR for the SLE cohort and the comparison cohort, stratified by three age groups.
The IRR for THR in SLE patients with the age of 20–44 years was marked elevated (adjusted IRR 7.70; 95% CI: 2.19–27.12, \(P = 0.001\)) compared with those in the comparison cohort. However, the IRRs for THR were not significantly different between the SLE cohort and the comparison cohort in patients aged 45–64 and 65–80. Moreover, no patients were found to receive TKR in the 20–44 years age group in the comparison cohort and no patients were found to receive TKR in the 65–80 years in the SLE cohort. The adjusted IRRs for TKR in all age groups were not significantly different between the SLE cohort and comparison cohort.

**Discussion**

In this secondary cohort analysis, we found that that young female patients with SLE suffered from a high incidence for receiving THR compared with the patients without SLE. Few studies have addressed the risk of THR and TKR in patients with SLE, and the incidence and incidence rate ratios compared with non-SLE patients were unclear. Mukherjee et al. reported that patients with SLE had an increased risk of receiving TKR, but not THR in a United Kingdom case-control study [11], which is different from our findings. The difference might be related to the different manifestations and severity of SLE in different ethnic groups (European versus Asian ancestry) [12].

In the young age group (20–44 years), patients with SLE exhibited more than 7-fold risk for receiving THR. Among these young patients with SLE, seven patients received THR due to osteonecrosis and one patient due to osteoarthritis. In the comparison cohort, three patients received THR due to osteoarthritis and one patient due to congenital abnormality of hip. Osteonecrosis is also known as avascular necrosis of bone, and it is the death of bone tissue related to a decreased in blood supply. Patients with osteonecrosis would suffer from the collapse of the bony structure, resulting in joint pain and loss of function. Patients with SLE are well known to have an increased risk of osteonecrosis [13]. Our study showed a large increased risk of THR, particularly in young SLE patients. This finding is consistent with a previous report in Korean patients with SLE [14]. The occurrence of osteonecrosis in patients with SLE could be affected by various factors. The long-term use of corticosteroid is certainly a strong risk factor of osteonecrosis, but neuropsychiatric manifestations of SLE, vasculitis, hypertension, serositis, and renal disease could also increase the risk of osteonecrosis [15]. In addition, it is estimated that more than half of the SLE patients who have osteonecrosis will progress and finally

**Table 1** Basic characteristics of the systemic lupus erythematosus cohort and comparison cohort (\(N = 3462\))

| Variable                        | \(n\) (%)   | \(P\) value |
|---------------------------------|-------------|-------------|
|                                | systemic lupus erythematosus cohort | comparison cohort |
| Age, years, mean (SD)          | 410 (14.7)  | 40.5 (12.9) | 0.432   |
| Obesity                        | 15 (2.6)    | 40 (1.4)    | 0.033   |
| Fracture of the lower limb     | 47 (8.1)    | 127 (4.4)   | < 0.001 |
| Socioeconomic status (\(n = 3364\)) |            |             |
| Low                             | 212 (37.7)  | 914 (32.6)  | 0.058   |
| Medium                         | 183 (32.6)  | 960 (34.3)  |         |
| High                            | 167 (29.7)  | 928 (33.1)  |         |
| Geographic region (\(n = 3361\)) |            |             |
| Northern                       | 352 (64.2)  | 1812 (64.4) | 0.646   |
| Central                        | 95 (17.3)   | 434 (15.4)  |         |
| Southern                       | 93 (16.9)   | 511 (18.2)  |         |
| Eastern                        | 9 (1.6)     | 55 (2.0)    |         |

SD standard deviation

**Table 2** Incidence rates and incidence rate ratios of surgery for systemic lupus erythematosus cohort and comparison cohort (\(N = 3462\))

| Type of surgery (ICD-9-CM) | No. of patients | Person-years | IR | No. of patients | Person-years | IR | IRR (95% CI) | \(a\)IRR (95% CI) | \(P\) value | \(P\) value |
|---------------------------|-----------------|--------------|----|-----------------|--------------|----|--------------|-----------------|-------------|-------------|
| THR (81.51)               | 12              | 3643.4       | 329.36 | 7              | 19,080.9  | 36.68 | 8.98 (3.53–22.80) < 0.001 | 6.47 (2.43–17.22) < 0.001 |
| TKR (81.54)               | 6               | 3659.9       | 163.94 | 15             | 19,042.0  | 78.77 | 2.08 (0.81–5.36) 0.129 | 1.81 (0.69–4.75) 0.227 |

\(a\)IRR adjusted incidence rate ratio, IR incidence rate, THR total hip replacement surgery, TKR total knee replacement surgery

\(a\)IRRs were adjusted for obesity, fracture of the lower limb, socioeconomic status, and geographic region
require surgical intervention [16]. The final treatment for severe osteonecrosis is a joint replacement surgery of the respective joints, which is an economic burden for both the healthcare system and the patients. Furthermore, patients with SLE receiving THR may suffer from a higher risk of surgical complications, such as deep vein thrombosis, acute kidney injury, and wound infections [17]. Therefore, the judicious use of corticosteroid with the addition of immunosuppressive agents is suggested to lower the risk of osteonecrosis. Early recognition and timely treatment for osteonecrosis is also important. Another potential cause of THR in patients with SLE is femoral neck fractures secondary to osteoporosis. However, we did not observe this cause of THR in the present study. Osteoporosis generally occurs in senile people, but the age of our SLE cohort is younger, which could explain the absence of THR due to femoral neck fracture attributed to osteoporosis.

Among the six patients with SLE who received TKR in this study, one patient was due to osteonecrosis and the remaining five patients were due to osteoarthritis. Osteoarthritis tends to develop in elderly patients, and since the SLE patients in this study were relatively young, they were less likely to receive TKR because of osteoarthritis.

Previous research indicated that obesity was a risk factor for receiving TKR and THR [18, 19], and patients with SLE can have a higher prevalence of obesity as a result of their long-term use of steroids. It should be noted that the identification of obesity in this study was based on the ICD-9-CM code 278.0x, which represents patients with morbid obesity. The prevalence of morbid obesity varies from 0.88% in Spain [20], 5% in UK [21], and 6% in USA [22]. The prevalence of morbid obesity in our comparison cohort was 1.4%, which is similar to that in Korea 0.9% [23].

A few limitations in this study should be noted. First, due to the restriction of the NHIRD, serological results for SLE and imaging reports for knee and hip joint were unavailable. Second, the diagnosis of SLE was based on catastrophic illness certificate. Nevertheless, the issue of the certificate was randomly audited by the NHIA to ensure their accuracy. Third, the risks of THR and TKR in male patients with SLE were not assessed due to the small sample size of male patients with SLE and milder degree of musculoskeletal system involvement in male patients with SLE [8]. Fourth, the data used in this study were retrospective in nature, and the need of prospective ad hoc studies will be required to overcome some of the aforementioned limitations.

**Conclusions**

In conclusion, this secondary cohort analysis of a nationwide, population-based health claims database showed that female patients with SLE had a higher risk of receiving THR, but not TKR. A high risk of receiving THR among young female SLE patients requires attention.

**Abbreviations**

ACR: American College of Rheumatology; aIRR: Adjusted incidence rate ratio; ICD-9-CM: International Classification of Diseases, 9th revision, Clinical Modification Declarations; IRR: Incidence rate ratio; LHIID: Longitudinal Health Insurance Database; NHIA: National Health Insurance Administration; NHIRD: National Health Insurance Research Database; SLE: Systemic lupus erythematosus; THR: Total hip replacement surgery; TKR: Total knee replacement surgery

**Acknowledgements**

The study is based in part on data from the National Health Insurance Research Database provided by the National Health Insurance Administration, Ministry of Health and Welfare and managed by the National Health Research Institutes. The interpretation and conclusions contained herein do not represent those of the National Health Insurance Administration, Ministry of Health and Welfare or the National Health Research Institutes.

We thank Dr. Malcolm Koo for his writing assistance and statistical advice.

**Authors’ contributions**

CHC and MCL participated in the conception and design of the study. CWH performed the data analysis. CHC and MCL prepared the manuscript. All authors read and approved the final manuscript.
Funding
None.

Availability of data and materials
The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to the Taiwan Personal Information Protection Act.

Ethics approval and consent to participate
This study was approved by the institutional review board of the Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Taiwan (No. B10104020), and was carried out in accordance with the ethical principles of the Declaration of Helsinki. The National Health Insurance Research Database (NHIRD) was initially available for research purposes after a successful application from the National Health Insurance Administration, Ministry of Health and Welfare. After a change in 2016, the NHIRD is currently regulated by the Data Science Centre of the Ministry of Health and Welfare, Taiwan. The NHIRD files contain de-identified secondary data, the need for informed consent from individual subjects was waived.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1Division of Obstetrics and Gynecology, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chiayi, Taiwan. 2Department of Medical Research, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chiayi, Taiwan. 3Division of Allergy, Immunology and Rheumatology, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, No. 2, Minsheng Road, Dalin, Chiayi 62247, Taiwan. 4School of Medicine, Tzu Chi University, Huaiian, Taiwan.

Received: 3 December 2018 Accepted: 27 June 2019
Published online: 06 July 2019

References
1. Lisnevskaia L, Murphy G, Isenberg D. Systemic lupus erythematosus. Lancet. 2014;384(9957):1878–88.
2. Lau CS, Yin G, Mok MY. Ethnic and geographical differences in systemic lupus erythematosus: an overview. Lupus. 2006;15(11):715–9.
3. Yeh KW, Yu CH, Chan PC, Hong JT, Huang JL. Burden of systemic lupus erythematosus in Taiwan: a population-based survey. Rheumatol Int. 2013;33(7):1805–11.
4. DiCruz DP, Khamashta MA, Hughes GR. Systemic lupus erythematosus. Lancet. 2007;369(9561):587–96.
5. Piga M, Saba L, Gabba A, Congia M, Balestrieri A, Mathieu A, Cauil A. Ultrasonographic assessment of bone erosions in the different subtypes of systemic lupus erythematosus arthritid: comparison with computed tomography. Arthritis Res Ther. 2016;18(1):222.
6. Mahmoud K, Zayat A, Vital EM. Musculoskeletal manifestations of systemic lupus erythematosus. Curr Opin Rheumatol. 2017;29(5):486–92.
7. Meretsmann-Voss C, Lyman S, Pan TJ, Goodman S, Figgie MP, Mandll JA. Arthroplasty rates are increased among US patients with systemic lupus erythematosus: 1991–2005. J Rheumatol. 2014;41(5):867–74.
8. Murphy G, Isenberg D. Effect of gender on clinical presentation in systemic lupus erythematosus. Rheumatology (Oxford). 2013;52(2):2108–15.
9. Lu MC, Tung CH, Yang CC, Wang CL, Huang KY, Koo M, Lai NS. Incident osteoarthritis and osteoarthritis-related joint replacement in patients with ankylosing spondylitis: a secondary cohort analysis of a nationwide, population-based health claims database. PLoS One. 2017;12:e0175394.
10. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40(9):1725.
11. Mulherjee S, Gullford D, Arden N, Edwards C. What is the risk of having a total hip or knee replacement for patients with lupus? Lupus. 2015;24(2):198–202.
12. Bochers AT, Naguwa SM, Shoenfeld Y, Gershwin ME. The geoepidemiology of systemic lupus erythematosus. Autoimmun Rev. 2010;9(5):A277–87.
13. Abu-Shakra M, Burikia D, Shoenfeld Y. Osteonecrosis in patients with SLE. Clin Rev Allergy Immunol. 2003;25(1):13–24.
14. Lee J, Kwok SK, Jung SM, Min HK, Nam HC, Seo JH, Ju J, Park KS, Park SH, Kim HY. Osteonecrosis of the hip in Korean patients with systemic lupus erythematosus: risk factors and clinical outcome. Lupus. 2014;23(1):39–45.
15. Hussein S, Satmier M, Béland-Bonenfant S, Bart-Dionne A, Vandermeer B, Santesso N, Keeling S, Pope JE, Fitt-Mah A, Bouré-Tessier J. Monitoring of osteonecrosis in systemic lupus erythematosus: a systematic review and meta-analysis. J Rheumatol. 2018;45(10):1462–76.
16. Gladman DD, Dhillon N, Su J, Urowitz MB. Osteonecrosis in SLE: prevalence, patterns, outcomes and predictors. Lupus. 2018;27:76–81.
17. Roberts JE, Mandll IA, Su EP, Maynoll DM, Figgie MP, Fein AW, Lee YY, Shah U, Goodman SM. Patients with systemic lupus erythematosus have increased risk of short-term adverse events after total hip arthroplasty. J Rheumatol. 2016;43(8):1498–502.
18. Hussain SM, Wang Y, Shaw JE, Wuik AE, Graves S, Gambhri M, Cuccitini FM. Relationship of weight and obesity with the risk of knee and hip arthroplasty for osteoarthritis across different levels of physical performance: a prospective cohort study. Scand J Rheumatol. 2019;48(1):64–71.
19. Wang Y, Simpson JA, Wuik AE, Teichtahl AJ, English DR, Giles GG, Graves S, Cuccitini FM. Relationship between body adiposity measures and risk of primary knee and hip replacement for osteoarthritis: a prospective cohort study. Arthritis Res Ther. 2009;11(2):R31.
20. Basterra-Gortari FJ, Bes-Rastrollo M, Ruiz-Canela M, Gea A, Martínez-González MA. Prevalence of obesity and diabetes in Spanish adults 1987–2012. Med Clin (Bcn). 2017;148(6):250–6.
21. Booth HP, Prevost AT, Gullford MC. Access to weight reduction interventions for overweight and obese patients in UK primary care: population-based cohort study. BMJ Open. 2015;5(1):e006642.
22. Plegal RM, Canoll MD, Ogden CL, Curtin LR. Prevalence and trends in obesity among US adults, 1999,2008. JAMA. 2010;303(3):235–41.
23. Cho WK, Han K, Ahn MB, Park YM, Jung MH, Sub BK, Park YG. Metabolic risk factors in Korean adolescents with severe obesity: results from the Korea National Health and nutrition examination surveys (K-NHANES) 2007–2014. Diabetes Res Clin Pract. 2018;138:169–76.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.